United States Generate Biomedicines Nasdaq IPO Share Price Decreased -20% on Day 1 Trading (27/2/26: IPO Price: $16, Closing $12.65) to $1.6 Billion Market Value & Raised $400 Million in IPO, Founded in 2018 by Molly Gibson & Gevorg Grigoryan
14th March 2026 | Hong Kong
United States clinical-stage biotechnology company Generate Biomedicines Nasdaq IPO share price decreased -20% on day 1 trading (27/2/26: IPO Price: $16, Closing $12.65) to $1.6 billion market value, raising $400 million in the IPO. In 2026 February, Generate Biomedicines Nasdaq IPO is raising $425 million at $2.2 billion valuation. Generate Biomedicines was founded in 2018 by Molly Gibson & Gevorg Grigoryan. Generate Biomedicines – Generate is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better medicines for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation.
“ United States Generate Biomedicines Nasdaq IPO Share Price Decreased -20% on Day 1 Trading (27/2/26: IPO Price: $16, Closing $12.65) to $1.6 Billion Market Value & Raised $400 Million in IPO, Founded in 2018 by Molly Gibson & Gevorg Grigoryan “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
United States Clinical-Stage Biotechnology Company Generate:Biomedicines Nasdaq IPO to Raise $425 Million at $2.2 Billion Valuation, Founded in 2018 by Molly Gibson & Gevorg Grigoryan
24th February 2026 – United States clinical-stage biotechnology company Generate Biomedicines Nasdaq IPO is raising $425 million at $2.2 billion valuation. Generate Biomedicines was founded in 2018 by Molly Gibson & Gevorg Grigoryan. Generate Biomedicines – Generate is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better medicines for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation.
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
